Compare RAIL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | KZIA |
|---|---|---|
| Founded | 1901 | 1994 |
| Country | United States | Australia |
| Employees | N/A | 10 |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.0M | 76.5M |
| IPO Year | 2005 | 2002 |
| Metric | RAIL | KZIA |
|---|---|---|
| Price | $4.27 | $4.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $10.67 | ★ $27.60 |
| AVG Volume (30 Days) | ★ 284.1K | 251.4K |
| Earning Date | 11-09-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $500,991,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.30 | N/A |
| P/E Ratio | $14.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.85 | $4.86 |
| 52 Week High | $14.90 | $17.40 |
| Indicator | RAIL | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 38.73 | 23.06 |
| Support Level | $3.94 | N/A |
| Resistance Level | $5.48 | $14.85 |
| Average True Range (ATR) | 0.35 | 0.69 |
| MACD | 0.07 | -0.20 |
| Stochastic Oscillator | 21.99 | 4.69 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Kazia Therapeutics Ltd is engaged in pharmaceutical drug development. The company is an emerging oncology-focused biotechnology company that has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. The company operates in one business segment, the research and development of pharmaceutical products in the field of oncology.